Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes.

MLA

Chen, Huey‐Ling, et al. “Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate in Pregnancy to Prevent HBV Transmission: Maternal ALT Trajectory and Infant Outcomes.” Liver International, vol. 44, no. 6, June 2024, pp. 1422–34. EBSCOhost, https://doi.org/10.1111/liv.15873.

APA

Chen, H., Lee, C., Chang, C., Lai, M., Tsai, M., Mu, S., Liu, C., Shih, J., Wen, W., Hu, R., Huang, C., Hu, K., Chen, C., Lee, C., Chien, R., Chang, K., Hsu, H., Lee, C., Ni, Y., & Chang, M. (2024). Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes. Liver International, 44(6), 1422–1434. https://doi.org/10.1111/liv.15873

Chicago

Chen, Huey‐Ling, Chien‐Nan Lee, Chin‐Hao Chang, Ming‐Wei Lai, Ming‐Chieh Tsai, Shu‐Chi Mu, Chun‐Jen Liu, et al. 2024. “Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate in Pregnancy to Prevent HBV Transmission: Maternal ALT Trajectory and Infant Outcomes.” Liver International 44 (6): 1422–34. doi:10.1111/liv.15873.